Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rotavirus Vaccines | 15 | 2023 | 53 | 6.100 |
Why?
|
| Rotavirus Infections | 13 | 2021 | 46 | 5.030 |
Why?
|
| Rotavirus | 10 | 2023 | 29 | 4.330 |
Why?
|
| Diarrhea | 15 | 2023 | 76 | 3.080 |
Why?
|
| Hospitalization | 31 | 2024 | 418 | 3.020 |
Why?
|
| Infant | 63 | 2025 | 2244 | 2.670 |
Why?
|
| Intussusception | 3 | 2021 | 6 | 2.200 |
Why?
|
| Respiratory Tract Infections | 14 | 2023 | 266 | 1.850 |
Why?
|
| Child, Preschool | 42 | 2022 | 1748 | 1.800 |
Why?
|
| Humans | 93 | 2025 | 14537 | 1.760 |
Why?
|
| South Africa | 69 | 2024 | 7596 | 1.660 |
Why?
|
| Child | 30 | 2023 | 2242 | 1.530 |
Why?
|
| Vaccination | 11 | 2025 | 365 | 1.460 |
Why?
|
| Gastroenteritis | 4 | 2023 | 22 | 1.420 |
Why?
|
| Incidence | 14 | 2021 | 685 | 1.380 |
Why?
|
| HIV Infections | 27 | 2024 | 5097 | 1.310 |
Why?
|
| Male | 49 | 2024 | 6754 | 1.290 |
Why?
|
| Female | 57 | 2025 | 9103 | 1.210 |
Why?
|
| Pneumococcal Vaccines | 6 | 2019 | 278 | 1.020 |
Why?
|
| Immunization Programs | 7 | 2025 | 81 | 0.990 |
Why?
|
| Pneumococcal Infections | 6 | 2019 | 299 | 0.950 |
Why?
|
| Vaccines, Subunit | 2 | 2020 | 8 | 0.840 |
Why?
|
| Antibodies, Viral | 8 | 2021 | 284 | 0.820 |
Why?
|
| Case-Control Studies | 9 | 2024 | 480 | 0.810 |
Why?
|
| Bacterial Infections | 3 | 2019 | 54 | 0.810 |
Why?
|
| Coinfection | 9 | 2019 | 276 | 0.790 |
Why?
|
| Infant, Newborn | 25 | 2025 | 1479 | 0.780 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 3 | 0.760 |
Why?
|
| Intestinal Perforation | 1 | 2021 | 5 | 0.760 |
Why?
|
| Prospective Studies | 21 | 2022 | 1160 | 0.730 |
Why?
|
| Metapneumovirus | 3 | 2023 | 30 | 0.730 |
Why?
|
| Immunogenicity, Vaccine | 3 | 2020 | 103 | 0.720 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.720 |
Why?
|
| Vaccines, Attenuated | 6 | 2023 | 28 | 0.720 |
Why?
|
| Cytomegalovirus Infections | 4 | 2021 | 23 | 0.720 |
Why?
|
| Health Behavior | 1 | 2021 | 79 | 0.710 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 11 | 0.690 |
Why?
|
| Influenza, Human | 9 | 2020 | 374 | 0.690 |
Why?
|
| Global Health | 5 | 2025 | 193 | 0.670 |
Why?
|
| Developing Countries | 4 | 2025 | 400 | 0.670 |
Why?
|
| Sentinel Surveillance | 6 | 2024 | 115 | 0.660 |
Why?
|
| Adult | 28 | 2024 | 5913 | 0.650 |
Why?
|
| Viruses | 6 | 2022 | 47 | 0.620 |
Why?
|
| Poverty | 1 | 2019 | 152 | 0.590 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 6 | 0.570 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2017 | 15 | 0.570 |
Why?
|
| Vaccines, Conjugate | 6 | 2021 | 171 | 0.540 |
Why?
|
| Bacteremia | 3 | 2014 | 79 | 0.520 |
Why?
|
| Pneumovirus Infections | 1 | 2015 | 7 | 0.500 |
Why?
|
| Adolescent | 17 | 2024 | 2985 | 0.500 |
Why?
|
| Caliciviridae Infections | 3 | 2023 | 11 | 0.490 |
Why?
|
| Staphylococcal Infections | 2 | 2012 | 31 | 0.490 |
Why?
|
| Milk, Human | 2 | 2015 | 23 | 0.480 |
Why?
|
| Haemophilus Vaccines | 4 | 2021 | 41 | 0.470 |
Why?
|
| Hepatitis B Vaccines | 5 | 2023 | 40 | 0.460 |
Why?
|
| Young Adult | 15 | 2024 | 2498 | 0.460 |
Why?
|
| Middle Aged | 17 | 2024 | 3601 | 0.460 |
Why?
|
| Retrospective Studies | 8 | 2021 | 799 | 0.460 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2019 | 200 | 0.450 |
Why?
|
| Staphylococcus aureus | 3 | 2012 | 43 | 0.450 |
Why?
|
| Immunoglobulin A | 4 | 2021 | 39 | 0.420 |
Why?
|
| Breast Feeding | 1 | 2014 | 120 | 0.420 |
Why?
|
| Epidemics | 2 | 2024 | 65 | 0.400 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 37 | 0.400 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 253 | 0.400 |
Why?
|
| Community-Acquired Infections | 2 | 2012 | 102 | 0.390 |
Why?
|
| Streptococcus pneumoniae | 7 | 2021 | 336 | 0.390 |
Why?
|
| Prevalence | 13 | 2022 | 1192 | 0.390 |
Why?
|
| Vaccines | 4 | 2025 | 86 | 0.390 |
Why?
|
| Acute Disease | 7 | 2021 | 105 | 0.380 |
Why?
|
| Immunization Schedule | 4 | 2022 | 81 | 0.370 |
Why?
|
| Virus Diseases | 3 | 2017 | 55 | 0.370 |
Why?
|
| Norovirus | 2 | 2023 | 5 | 0.360 |
Why?
|
| Immunization, Secondary | 4 | 2023 | 72 | 0.360 |
Why?
|
| Cohort Studies | 6 | 2022 | 967 | 0.350 |
Why?
|
| Pneumonia, Bacterial | 3 | 2016 | 54 | 0.350 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2021 | 529 | 0.340 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 231 | 0.330 |
Why?
|
| Antibody Formation | 3 | 2023 | 61 | 0.330 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 3 | 2021 | 11 | 0.300 |
Why?
|
| Double-Blind Method | 2 | 2020 | 272 | 0.300 |
Why?
|
| Cytomegalovirus | 4 | 2021 | 24 | 0.290 |
Why?
|
| Pregnancy | 8 | 2025 | 1862 | 0.290 |
Why?
|
| Tetanus | 2 | 2021 | 10 | 0.280 |
Why?
|
| Diphtheria | 2 | 2021 | 16 | 0.280 |
Why?
|
| Aged | 12 | 2024 | 1740 | 0.280 |
Why?
|
| Hepatitis B | 2 | 2023 | 125 | 0.270 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2019 | 155 | 0.270 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2019 | 472 | 0.270 |
Why?
|
| Hospital Mortality | 5 | 2021 | 95 | 0.260 |
Why?
|
| Cost of Illness | 2 | 2019 | 167 | 0.260 |
Why?
|
| Public Health | 2 | 2024 | 124 | 0.250 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2019 | 73 | 0.250 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2021 | 28 | 0.250 |
Why?
|
| Paramyxoviridae Infections | 2 | 2023 | 27 | 0.240 |
Why?
|
| Pneumonia, Pneumococcal | 3 | 2015 | 100 | 0.240 |
Why?
|
| Nasopharynx | 8 | 2021 | 151 | 0.230 |
Why?
|
| Risk Factors | 10 | 2019 | 1475 | 0.230 |
Why?
|
| Sepsis | 3 | 2015 | 102 | 0.230 |
Why?
|
| C-Reactive Protein | 2 | 2021 | 96 | 0.220 |
Why?
|
| Viral Vaccines | 1 | 2023 | 24 | 0.220 |
Why?
|
| Carrier State | 2 | 2014 | 92 | 0.210 |
Why?
|
| Laboratory Infection | 1 | 2023 | 5 | 0.210 |
Why?
|
| Pneumonia | 2 | 2017 | 131 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 303 | 0.210 |
Why?
|
| Population Surveillance | 4 | 2017 | 325 | 0.200 |
Why?
|
| HIV Seropositivity | 2 | 2023 | 265 | 0.200 |
Why?
|
| Time Factors | 4 | 2022 | 507 | 0.200 |
Why?
|
| Seasons | 3 | 2020 | 154 | 0.200 |
Why?
|
| Enema | 1 | 2021 | 3 | 0.190 |
Why?
|
| Up-Regulation | 1 | 2021 | 23 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 22 | 0.190 |
Why?
|
| Antibodies, Bacterial | 4 | 2021 | 153 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 77 | 0.180 |
Why?
|
| Growth and Development | 1 | 2020 | 4 | 0.180 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 14 | 0.180 |
Why?
|
| Vagina | 2 | 2012 | 91 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 146 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 260 | 0.180 |
Why?
|
| Urban Population | 3 | 2021 | 257 | 0.180 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2017 | 28 | 0.180 |
Why?
|
| Isoantibodies | 1 | 2020 | 15 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2021 | 149 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2022 | 132 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2020 | 49 | 0.170 |
Why?
|
| Poliovirus Vaccine, Inactivated | 3 | 2021 | 17 | 0.170 |
Why?
|
| Immunization | 1 | 2020 | 63 | 0.170 |
Why?
|
| HLA Antigens | 1 | 2020 | 50 | 0.170 |
Why?
|
| United States | 1 | 2020 | 132 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 1 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 5 | 0.170 |
Why?
|
| Kenya | 1 | 2020 | 183 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2012 | 293 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1422 | 0.160 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 563 | 0.160 |
Why?
|
| Mamastrovirus | 1 | 2018 | 3 | 0.160 |
Why?
|
| Astroviridae Infections | 1 | 2018 | 3 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 77 | 0.150 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2020 | 40 | 0.150 |
Why?
|
| Streptococcus agalactiae | 3 | 2015 | 202 | 0.150 |
Why?
|
| Hypertension | 1 | 2022 | 419 | 0.140 |
Why?
|
| Placebos | 1 | 2017 | 44 | 0.140 |
Why?
|
| Administration, Oral | 2 | 2015 | 127 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 150 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 34 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2017 | 55 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2019 | 889 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2022 | 171 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2022 | 543 | 0.140 |
Why?
|
| Data Collection | 1 | 2017 | 86 | 0.140 |
Why?
|
| Odds Ratio | 3 | 2022 | 133 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 77 | 0.130 |
Why?
|
| Sapovirus | 1 | 2016 | 6 | 0.130 |
Why?
|
| Genotype | 1 | 2017 | 442 | 0.130 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2015 | 10 | 0.120 |
Why?
|
| Rural Population | 2 | 2021 | 654 | 0.120 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 11 | 0.120 |
Why?
|
| Vaccines, Combined | 4 | 2021 | 34 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 23 | 0.120 |
Why?
|
| Streptococcal Infections | 2 | 2015 | 184 | 0.120 |
Why?
|
| Bronchopneumonia | 1 | 2015 | 11 | 0.120 |
Why?
|
| Suburban Population | 1 | 2014 | 9 | 0.120 |
Why?
|
| Hospitals | 3 | 2023 | 103 | 0.120 |
Why?
|
| HIV-1 | 1 | 2023 | 1260 | 0.120 |
Why?
|
| Immunogenetic Phenomena | 1 | 2014 | 7 | 0.110 |
Why?
|
| Feces | 3 | 2019 | 30 | 0.110 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Chickenpox Vaccine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Tetanus Toxoid | 1 | 2013 | 14 | 0.110 |
Why?
|
| Logistic Models | 3 | 2022 | 254 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 104 | 0.110 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 23 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 468 | 0.100 |
Why?
|
| Hospitals, Public | 2 | 2022 | 45 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 2012 | 7 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2012 | 9 | 0.100 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2012 | 16 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 57 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 324 | 0.090 |
Why?
|
| Poliovirus Vaccines | 1 | 2011 | 11 | 0.090 |
Why?
|
| Serotyping | 3 | 2015 | 66 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 90 | 0.090 |
Why?
|
| Quality of Life | 2 | 2022 | 177 | 0.090 |
Why?
|
| Whooping Cough | 1 | 2011 | 36 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 195 | 0.090 |
Why?
|
| Chlorhexidine | 1 | 2009 | 10 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.080 |
Why?
|
| Skin | 1 | 2009 | 38 | 0.080 |
Why?
|
| Labor, Obstetric | 1 | 2009 | 44 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 6 | 0.080 |
Why?
|
| Age Factors | 3 | 2015 | 370 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 370 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2016 | 64 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 2 | 2021 | 551 | 0.060 |
Why?
|
| Bacterial Load | 2 | 2014 | 32 | 0.060 |
Why?
|
| ROC Curve | 2 | 2017 | 51 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2023 | 10 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 48 | 0.050 |
Why?
|
| Government | 1 | 2022 | 13 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.050 |
Why?
|
| Seroconversion | 1 | 2021 | 5 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2022 | 64 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 53 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 42 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 157 | 0.050 |
Why?
|
| Placental Circulation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2020 | 18 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2021 | 175 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 22 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2020 | 77 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 296 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 83 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2019 | 1 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2019 | 2 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 3 | 0.040 |
Why?
|
| Scotland | 1 | 2019 | 5 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 9 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 22 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 26 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 26 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 106 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 45 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 367 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 80 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 385 | 0.040 |
Why?
|
| Control Groups | 1 | 2017 | 3 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 21 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2017 | 64 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 6 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 30 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 107 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 81 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 231 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 47 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 52 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2017 | 303 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 21 | 0.030 |
Why?
|
| Serum | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 42 | 0.030 |
Why?
|
| Models, Biological | 1 | 2015 | 77 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 52 | 0.030 |
Why?
|
| Streptococcal Vaccines | 1 | 2015 | 47 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2014 | 42 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2014 | 28 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 104 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2014 | 42 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 188 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2015 | 198 | 0.030 |
Why?
|
| Mass Screening | 1 | 2016 | 245 | 0.030 |
Why?
|
| Child Day Care Centers | 1 | 2013 | 4 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 411 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 435 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 45 | 0.030 |
Why?
|
| Oropharynx | 1 | 2012 | 17 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2012 | 30 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2013 | 135 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 35 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2012 | 56 | 0.020 |
Why?
|
| Klebsiella pneumoniae | 1 | 2012 | 39 | 0.020 |
Why?
|
| Latin America | 1 | 2012 | 10 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 56 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 39 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2012 | 97 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 112 | 0.020 |
Why?
|
| Pneumocystis carinii | 1 | 2011 | 9 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 244 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 199 | 0.020 |
Why?
|
| Infant Care | 1 | 2009 | 10 | 0.020 |
Why?
|
| Bacteria | 1 | 2009 | 47 | 0.020 |
Why?
|
| HIV | 1 | 2012 | 380 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 25 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2008 | 13 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2008 | 54 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 225 | 0.020 |
Why?
|